Obinutuzumab (anti-CD20)

Ask supplier a question | View on supplier's website

Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.

Supplier	Selleck Chemicals
Product #	A2023
Sku #	A2023-1mg*5
Pricing	1mg*5, $979.00

Feedback